Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases - PubMed (original) (raw)
Review
. 2007 Apr-May;59(4-5):332-45.
doi: 10.1080/15216540701283882.
Affiliations
- PMID: 17505973
- DOI: 10.1080/15216540701283882
Free article
Review
Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases
Sergio T Ferreira et al. IUBMB Life. 2007 Apr-May.
Free article
Abstract
Amyloid diseases are a group of degenerative disorders characterized by cell/tissue damage caused by toxic protein aggregates. Abnormal production, processing and/or clearance of misfolded proteins or peptides may lead to their accumulation and to the formation of amyloid aggregates. Early histopathological investigation of affected organs in different amyloid diseases revealed the ubiquitous presence of fibrillar protein aggregates forming large deposits known as amyloid plaques. Further in vitro biochemical and cell biology studies, as well as studies using transgenic animal models, provided strong support to what initially seemed to be a solid concept, namely that amyloid fibrils played crucial roles in amyloid pathogenesis. However, recent studies describing tissue-specific accumulation of soluble protein oligomers and their strong impact on cell function have challenged the fibril hypothesis and led to the emergence of a new view: Fibrils are not the only toxins derived from amyloidogenic proteins and, quite possibly, not the most important ones with respect to disease etiology. Here, we review some of the recent findings and concepts in this rapidly developing field, with emphasis on the involvement of soluble oligomers of the amyloid-beta peptide in the pathogenesis of Alzheimer's disease. Recent studies suggesting that soluble oligomers from different proteins may share common mechanisms of cytotoxicity are also discussed. Increased understanding of the cellular toxic mechanisms triggered by protein oligomers may lead to the development of rational, effective treatments for amyloid disorders.
Similar articles
- Soluble oligomers from a non-disease related protein mimic Abeta-induced tau hyperphosphorylation and neurodegeneration.
Vieira MN, Forny-Germano L, Saraiva LM, Sebollela A, Martinez AM, Houzel JC, De Felice FG, Ferreira ST. Vieira MN, et al. J Neurochem. 2007 Oct;103(2):736-48. doi: 10.1111/j.1471-4159.2007.04809.x. Epub 2007 Aug 28. J Neurochem. 2007. PMID: 17727639 - Protein denaturation and aggregation: Cellular responses to denatured and aggregated proteins.
Meredith SC. Meredith SC. Ann N Y Acad Sci. 2005 Dec;1066:181-221. doi: 10.1196/annals.1363.030. Ann N Y Acad Sci. 2005. PMID: 16533927 Review. - Soluble amyloid beta oligomers may contribute to apoptosis of retinal ganglion cells in glaucoma.
Yin H, Chen L, Chen X, Liu X. Yin H, et al. Med Hypotheses. 2008;71(1):77-80. doi: 10.1016/j.mehy.2008.01.030. Epub 2008 Apr 11. Med Hypotheses. 2008. PMID: 18406539 - Conformation-dependent anti-amyloid oligomer antibodies.
Kayed R, Glabe CG. Kayed R, et al. Methods Enzymol. 2006;413:326-44. doi: 10.1016/S0076-6879(06)13017-7. Methods Enzymol. 2006. PMID: 17046404 - Common mechanisms of amyloid oligomer pathogenesis in degenerative disease.
Glabe CG. Glabe CG. Neurobiol Aging. 2006 Apr;27(4):570-5. doi: 10.1016/j.neurobiolaging.2005.04.017. Epub 2006 Feb 14. Neurobiol Aging. 2006. PMID: 16481071 Review.
Cited by
- Treatment of Stargardt disease with dobesilate.
Cuevas P, Outeiriño LA, Angulo J, Giménez-Gallego G. Cuevas P, et al. BMJ Case Rep. 2012 Oct 12;2012:bcr2012007128. doi: 10.1136/bcr-2012-007128. BMJ Case Rep. 2012. PMID: 23076703 Free PMC article. - Human apolipoprotein A-I natural variants: molecular mechanisms underlying amyloidogenic propensity.
Ramella NA, Schinella GR, Ferreira ST, Prieto ED, Vela ME, Ríos JL, Tricerri MA, Rimoldi OJ. Ramella NA, et al. PLoS One. 2012;7(8):e43755. doi: 10.1371/journal.pone.0043755. Epub 2012 Aug 28. PLoS One. 2012. PMID: 22952757 Free PMC article. - The pathophysiology of defective proteostasis in the hypothalamus - from obesity to ageing.
Cavadas C, Aveleira CA, Souza GF, Velloso LA. Cavadas C, et al. Nat Rev Endocrinol. 2016 Dec;12(12):723-733. doi: 10.1038/nrendo.2016.107. Epub 2016 Jul 8. Nat Rev Endocrinol. 2016. PMID: 27388987 Review. - Characterization of the interaction of β-amyloid with transthyretin monomers and tetramers.
Du J, Murphy RM. Du J, et al. Biochemistry. 2010 Sep 28;49(38):8276-89. doi: 10.1021/bi101280t. Biochemistry. 2010. PMID: 20795734 Free PMC article. - A rare case of primary thyroid amyloidosis.
Cannizzaro MA, Lo Bianco S, Saliba W, D'Errico S, Pennetti Pennella F, Buttafuoco G, Provenzano D, Magro G. Cannizzaro MA, et al. Int J Surg Case Rep. 2018;53:179-181. doi: 10.1016/j.ijscr.2018.10.033. Epub 2018 Oct 25. Int J Surg Case Rep. 2018. PMID: 30408741 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical